Therapeutics

Top Story

Latanoprostene bunod reduces IOP, ocular hypertension

July 20, 2016

BOSTON – Once daily latanoprostene bunod 0.024%, taken in the evening, reduced IOP in subjects with open angle glaucoma or ocular hypertension significantly, compared to the IOP-lowering capability of timolol 0.5% twice daily, according to a poster presented by Murray Fingeret, OD, and Jason L. Vittitow, PhD, here at Optometry’s Meeting.

A total of 774 subjects completed 3 months of follow-up across two phase 3, multicenter, parallel-group, non-inferiority studies in which subjects 18 years and older were randomized to double-masked treatment with either latanoprostene bunod (LBN) 0.024% once daily at night or timolol 0.5% twice daily.

Meeting News Coverage

Study finds marketing affects prescribing behavior

July 13, 2016
BOSTON – Optometrists earned more than $18 million in 2014 as a result of financial relationships with the medical industry, according to a study presented here at…
FDA News

FDA approves lifitegrast for signs, symptoms of dry eye

July 12, 2016
The FDA announced today that it approved lifitegrast for treating the signs and symptoms of dry eye disease in adults on July 11. Xiidra (lifitegrast ophthalmic solution…
Meeting News Coverage

Free service assists with prior authorizations for prescriptions

July 2, 2016
BOSTON – PARx helps physicians through the process when a drug they prescribe requires prior authorization from the insurer. Dan Rubin, PARx Solutions…
In the Journals

Macular carotenoids can have positive effects on visual function

July 19, 2016
Researchers found that in subjects free of retinal disease and with low macular pigment, supplementation with a…
More »
Meeting News Coverage

Latanoprostene bunod reduces IOP, ocular hypertension

July 20, 2016
BOSTON – Once daily latanoprostene bunod 0.024%, taken in the evening, reduced IOP in subjects with open angle…
More »
Featured
Optometry's Meeting 2016

Optometry's Meeting 2016

Perspectives on Glaucoma

Study: Perimetry detects progression before photography in eyes with field loss

July 21, 2016
Progression in the visual field was detected first, more than four times as often as progression in the optic disc, in…
More »
Meeting News Coverage

Latanoprostene bunod reduces IOP, ocular hypertension

July 20, 2016
BOSTON – Once daily latanoprostene bunod 0.024%, taken in the evening, reduced IOP in subjects with open angle glaucoma or ocular hypertension…

Meeting News Coverage

Study finds marketing affects prescribing behavior

July 13, 2016
BOSTON – Optometrists earned more than $18 million in 2014 as a result of financial relationships with the medical industry, according to a…

FDA News

FDA approves lifitegrast for signs, symptoms of dry eye

July 12, 2016
The FDA announced today that it approved lifitegrast for treating the signs and symptoms of dry eye disease in adults on July 11. Xiidra (lifitegrast…

Meeting News Coverage

Free service assists with prior authorizations for prescriptions

July 2, 2016
BOSTON – PARx helps physicians through the process when a drug they prescribe requires prior authorization from the insurer. Dan

Meeting News CoverageVideo

Ferrucci: ODs play important role in diabetes for whole body health, not just vision

June 30, 2016
BOSTON – Steven Ferrucci, OD, FAAO, discusses the systemic aspects of diabetes here at Optometry’s Meeting. Ferrucci is chief of…

Perspectives on GlaucomaPerspective

Latanoprostene bunod once daily found noninferior to timolol three times daily

June 20, 2016
Researchers found that daily evening treatments of latanoprostene bunod were noninferior to timolol twice daily for 3 months and resulted in…

Perspectives on Glaucoma

Researchers find association between statin use, glaucoma incidence

June 15, 2016
Short-term statin use was found to be associated with a reduced incidence of glaucoma, but no association was found with IOP, according to a study in…

Low-tech wearable device addresses issues with patient compliance

Primary Care Optometry News, June 2016
A new modular device may help increase compliance rates among patients taking ocular medications. A study by Okeke and colleagues showed that 45% of…

BLOG: Three reasons why MIGS may replace drops as first-line therapy

June 10, 2016
The use of minimally invasive glaucoma surgery has grown in the U.S. Here are three reasons why our old standard glaucoma drops may one day be…

Topical EV06 improves near vision in patients with presbyopia

June 9, 2016
Twice-daily treatment with one drop of EV06 ophthalmic solution 1.5% improved distance-corrected near vision acuity efficacy measures when compared…

More Headlines »
morganatic-roan